Abstract
Current treatment for HCV infections consists of approved direct acting antivirals (DAAs), viz. the protease inhibitors (boceprevir, telaprevir, and simeprevir), NS5B polymerase inhibitors (sofosbuvir) and NS5A inhibitor (ledipasvir) in combination with pegylated interferon α and ribavirin). These treatments have made a great improvement in the treatment of chronic HCV infections in recent years, but their adverse side effects, emergence of resistant mutants, high cost, and increased pill burden have limited their clinical use. Recently, with the increasing knowledge in understanding the HCV life cycle, more targets have been recognized. NS5A protein plays a critical role in assembly of infectious HCV particles and offering potential for HCV therapies. Therefore, discovery and development of novel DAAs targeting NS5A with novel mechanisms of action, are of great necessity to improve the quality of existing HCV treatments. In the present review, we discuss recent advances with NS5A inhibitors with potent anti-HCV activity, and the potential for the development of HCV NS5A inhibitors to combat HCV infections.
Keywords: Antivirals, drug design, HCV, hepatitis, inhibitors, NS5A.
Current Medicinal Chemistry
Title:The Changing Face of Hepatitis C: Recent Advances on HCV Inhibitors Targeting NS5A
Volume: 22 Issue: 15
Author(s): Diwakar Rai, Liu Wang, Xuemei Jiang, Peng Zhan, Haiyong Jia, Erik De Clercq and Xinyong Liu
Affiliation:
- Department of Hepatic Diseases, Jinan Infectious Disease Hospital, Jingshi Road, 173,250021, Jinan, Shandong, P. R. China.,China
Keywords: Antivirals, drug design, HCV, hepatitis, inhibitors, NS5A.
Abstract: Current treatment for HCV infections consists of approved direct acting antivirals (DAAs), viz. the protease inhibitors (boceprevir, telaprevir, and simeprevir), NS5B polymerase inhibitors (sofosbuvir) and NS5A inhibitor (ledipasvir) in combination with pegylated interferon α and ribavirin). These treatments have made a great improvement in the treatment of chronic HCV infections in recent years, but their adverse side effects, emergence of resistant mutants, high cost, and increased pill burden have limited their clinical use. Recently, with the increasing knowledge in understanding the HCV life cycle, more targets have been recognized. NS5A protein plays a critical role in assembly of infectious HCV particles and offering potential for HCV therapies. Therefore, discovery and development of novel DAAs targeting NS5A with novel mechanisms of action, are of great necessity to improve the quality of existing HCV treatments. In the present review, we discuss recent advances with NS5A inhibitors with potent anti-HCV activity, and the potential for the development of HCV NS5A inhibitors to combat HCV infections.
Export Options
About this article
Cite this article as:
Rai Diwakar, Wang Liu, Jiang Xuemei, Zhan Peng, Jia Haiyong, De Clercq Erik and Liu Xinyong, The Changing Face of Hepatitis C: Recent Advances on HCV Inhibitors Targeting NS5A, Current Medicinal Chemistry 2015; 22(15) . https://dx.doi.org/10.2174/0929867322666150209150920
DOI https://dx.doi.org/10.2174/0929867322666150209150920 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Preliminary Pharmacological Screening of Some Thiosemicarbazide, s-triazole, and Thiadiazole Derivatives
CNS & Neurological Disorders - Drug Targets Therapeutic Potential of Targeting Protease Activated Receptors in Cardiovascular Diseases
Current Pharmaceutical Design Targeting Complement in Rheumatoid Arthritis
Current Rheumatology Reviews ISCHEMIRs: Finding a Way Through the Obstructed Cerebral Arteries
Current Drug Targets “SLY AS A FOXO”: New Paths with Forkhead Signaling in the Brain
Current Neurovascular Research Aspartic Protease Inhibitors as Potential Anti-Candida albicans Drugs: Impacts on Fungal Biology, Virulence and Pathogenesis
Current Medicinal Chemistry Drug Transport Across the Placenta
Current Pharmaceutical Biotechnology Proteomic Analyses of a Variety of Intracellular Bacterial Species Infecting Different Host Cell Lines
Current Proteomics The Use of Lentinan for Treating Gastric Cancer
Anti-Cancer Agents in Medicinal Chemistry Aptamers: Molecular Tools for Medical Diagnosis
Current Topics in Medicinal Chemistry Anti-annexin A5, Antiphosphatidylinositol Antibodies, and Haematological Parameters in Preeclampsia Patients: A Case-Control Study
Current Women`s Health Reviews Targeting Malignancies with Disulfiram (Antabuse): Multidrug Resistance, Angiogenesis, and Proteasome
Current Cancer Drug Targets Antiretroviral Treatment of HIV Infection Does Not Influence HIVSpecific Immunity but Has an Impact on Non-Specific Immune Activation
Current HIV Research Molecular Docking Studies of Novel Arylidene-2, 4-Thiazolidinediones as Potential Aldose Reductase Inhibitors
Letters in Drug Design & Discovery Preface- Novel Targets for CNS Anti-Inflammatory Drug Development Interfering with Eicosanoid Formation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Short Bioactive Marine Oligosaccharides: Diving into Recent Literature
Current Biotechnology Adoptive Regulatory T-cell Therapy Attenuates Subarachnoid Hemor-rhage-induced Cerebral Inflammation by Suppressing TLR4/NF-B Signaling Pathway
Current Neurovascular Research Subject Index To Volume 5
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Morphological and Histopathological Study of Autopsied Patients with Atherosclerosis and HIV
Current HIV Research Patents on Non-Viral Mediated Gene Delivery
Recent Patents on DNA & Gene Sequences